Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Mar 20, 2024 9:28pm
124 Views
Post# 35944122

RE:RE:MSD Merck on the lookout for new opportunities within immuno

RE:RE:MSD Merck on the lookout for new opportunities within immunoAlong with checkpoint inhibitors, oncolytic virus are listed as an immunotherapy for the treatment of cancer 

https://www.mdanderson.org/cancerwise/what-cancers-can-be-treated-with-immunotherapy.h00-159386679.html

Immune checkpoint inhibitors are one of several types of immunotherapy. Other forms include:
 
- Adoptive cellular therapies such as chimeric antigen receptor (CAR) T cell therapies, are immune cells taken from a patient or healthy donor and modified to boost their ability to eliminate cancer.
- Targeted antibodies are treatments that mimic naturally occurring antibodies from our immune system.
- Cancer vaccines train the body to recognize specific features of cancer and stimulate an immune response.
- Oncolytic viruses use engineered viruses to infect and destroy cancer cells.
- Immune system modulators, or cytokine therapies, use immune signaling compounds to stimulate immune activity.
<< Previous
Bullboard Posts
Next >>